Key sentence from the paper: “More fit patients…are less at risk [of cardiovascular disease], and [this] supports the view that those patients on ADT with preesxisting cardiovascular disease may be at a greater risk.” 

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. By Gonzalez et al. 2015 

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. By Harshman et al. 2015

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture. By Wilson et al. 2015

Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. By Keane et al. 2015 

Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. By Ludwig et al. 2015

Key sentence from the paper: “…the PCa patients in the ADT group performed significantly worse than those of age- and education-matched patients in the non-ADT group and [healthy controls] on the neuropsychological tests assessing memory, attention and information processing, indicating ADT impaired cognition in Chinese PCa patients...”

Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. By Nguyen et al. 2015

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. By McKay et al. 2015 

Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. By Gunnarsson et al. 2015